Costco Wholesale will pay $11.75 million to resolve claims that some of its pharmacies filled improper or incomplete prescriptions for controlled substances » Read More
Walgreens settles U.S. lawsuit that accuses company of incentivizing the fulfillment of government healthcare prescriptions. » Read More
Mallinckrodt has agreed to pay $100 million to settle allegations that it broke U.S. antitrust law by sharply increasing the price of a multiple sclerosis drug. » Read More
Mallinkrodt was being investigated in connection with big price increases for its drug Achthar Gel.
Merck Group CEO Stefan Oschmann discusses his outlook for 2017 and how big data is transforming the pharmaceuticals industry.
Novartis CEO Joe Jimenez discusses investment in the United States under U.S. President-elect Donald Trump.
Merck Group CEO Stefan Oschmann speaks about how his world has changed after Donald Trump's election.
Novartis CEO Joe Jimenez discusses how his sector may develop under Donald Trump's presidency.
Steve Brozak at WBB Securities explains why he favors Omeros stocks.
The lack of clarity over Trump’s policies was so great that fund manager Invesco is reducing risk exposure, a senior portfolio manager said.
The new CMS classification means the device is eligible for Medicaid and Medicare coverage.
It's becoming obvious Big Pharma's iron wall of protection in Washington is starting to crumble, says Jake Novak.
Price and Rep. Chris Collins, R-N.Y., got a 12 percent discount in their private placement purchase of stock in an Australian drug company.
"Sugar Goggles," a virtual reality game, is hoping to encourage children to make healthier eating choices and adjust eating habits.
When someone goes into opioid overdose, their body begins shutting down. But there’s a drug that can stop the process. Naloxone has saved the thousands of people after they overdosed. Here’s how it works.
A U.S. appeals court said Eli Lilly may block Teva Pharmaceutical from selling a generic equivalent of its top-selling lung cancer drug Alimta.
Investor optimism regarding the outlook for European healthcare stocks continued to decline dramatically on Thursday.
Morgan Stanley's 2020 earnings-per-share estimate for Merck is $5.82 versus the Wall Street consensus of $4.97.
Andrew Keene at KeeneOnTheMarket.com says that Trump is still better for pharmaceutical stocks than Clinton would have been.
Get the best of CNBC in your inbox